Aerosol pentamidine-induced bronchoconstriction. Predictive factors and preventive therapy
- PMID: 1832372
- DOI: 10.1378/chest.100.3.624
Aerosol pentamidine-induced bronchoconstriction. Predictive factors and preventive therapy
Abstract
Objective: To describe the frequency of aerosol pentamidine-induced bronchoconstriction, its relationship to non-specific airway responsiveness, and its response to preventive therapy using salbutamol, ipratropium bromide, or sodium cromoglycate.
Methods: Consecutive HIV-infected individuals starting prophylactic AP were eligible if they had not been previously treated with this agent. Simple spirometry was performed before and 10 min after a single 60-mg dose given through an ultrasonic nebulizer. Methacholine challenge was performed in all subjects 24 h to four days after the initial AP dose. Subjects with a change in FEV1 (delta FEV1) greater than or equal to 10 percent decrease after the initial AP dose were restudied on three separate occasions (greater than 24 hours apart) after premedication with two puffs of salbutamol (200 micrograms), ipratropium bromide (40 micrograms), or sodium cromoglycate (2 mg), in random order.
Results: Fifty-three subjects were studied. The median delta FEV1 after a single dose of AP was -7.0 percent (range: -47 percent, 1.8 percent). The delta FEV1 following AP was only partially predicted by the degree of nonspecific bronchial responsiveness as measured by a standard methacholine challenge. Age, current smoking, history of asthma, baseline FEV1, or a prior episode of PCP failed to predict the delta FEV1 following AP. Eighteen subjects (34 percent) had a delta FEV1 greater than or equal to 10 percent decrease (median: -17.0 percent). In these subjects, after premedication with salbutamol, ipratropium bromide, and sodium cromoglycate, the median delta FEV1 was 1.0, 0.8, and -9.6 percent, respectively.
Conclusion: Aerosol pentamidine produced a decrease in FEV1 greater than or equal to 10 percent in 34 percent of subjects. This was not accurately predicted by the methacholine response. The bronchoconstriction induced by AP was effectively prevented by either salbutamol or ipratropium, whereas cromoglycate was only partially effective.
Similar articles
-
Lack of desensitization to aerosol pentamidine with long-term use.J Aerosol Med. 1996 Summer;9(2):241-8. doi: 10.1089/jam.1996.9.241. J Aerosol Med. 1996. PMID: 10163353
-
Decreased bronchodilating effect of salbutamol in relieving methacholine induced moderate to severe bronchoconstriction during high dose treatment with long acting beta2 agonists.Thorax. 2001 Jul;56(7):529-35. doi: 10.1136/thorax.56.7.529. Thorax. 2001. PMID: 11413351 Free PMC article. Clinical Trial.
-
Same efficacies of ipratropium and salbutamol in reversing methacholine-induced bronchoconstriction.J Asthma. 2006 Nov;43(9):679-85. doi: 10.1080/02770900600925502. J Asthma. 2006. PMID: 17092849
-
Effects of ipratropium bromide nebulizer solution with and without preservatives in the treatment of acute and stable asthma.Chest. 1992 Sep;102(3):742-7. doi: 10.1378/chest.102.3.742. Chest. 1992. PMID: 1387604 Clinical Trial.
-
A comparison of several agents with two delivery systems for the prevention of airway narrowing induced by nebulised pentamidine isethionate.Respir Med. 1991 Nov;85(6):527-31. doi: 10.1016/s0954-6111(06)80272-6. Respir Med. 1991. PMID: 1663642
Cited by
-
Adverse drug events related to dosage forms and delivery systems.Drug Saf. 1996 Jan;14(1):39-67. doi: 10.2165/00002018-199614010-00005. Drug Saf. 1996. PMID: 8713487 Review.
-
Tolerance and efficacy of Amphotericin B inhalations for prevention of invasive pulmonary aspergillosis in haematological patients.Eur J Clin Microbiol Infect Dis. 1997 May;16(5):364-8. doi: 10.1007/BF01726364. Eur J Clin Microbiol Infect Dis. 1997. PMID: 9228476 Clinical Trial.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources